One of the most notable changes is a new thematic structure within urologic oncology. In this video, Bruno Nahar, MD, an associate professor of urologic oncology and the Eric and Elizabeth Feder ...
The study assessed descriptive sequencing and oncologic outcomes among patients receiving gene therapy for BCG-unresponsive NMIBC. Data presented at the 2025 Society of Urology Oncology Annual Meeting ...
In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC. Teoh ...
Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. On December 9, 2025, Artera announced the commercial launch of the ArteraAI ...
The Vanquish Water Vapor System and Hugo robotic-assisted surgery system received FDA clearance for prostate cancer and urologic procedures, respectively, demonstrating high effectiveness and safety.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
FDA approved Gozellix for prostate cancer imaging and expanded 177Lu-PSMA-617's label for mCRPC treatment. 64Cu-SAR-bisPSMA demonstrated efficacy in detecting recurrent prostate cancer in the COBRA ...
Rucaparib is now approved for BRCA mutation-associated mCRPC patients post-androgen receptor therapy, without prior chemotherapy requirement. The TRITON3 trial showed significant improvement in ...
Hormonal changes influence fluid balance and bloating, increasing pressure within the pelvis. In this video, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, founder of the Fosnight Center ...
The combination yielded significant improvements in event-free survival, overall survival, and pathologic complete response rates vs neoadjuvant chemotherapy. Topline results from the phase 3 ...
Maxwell L. Sandberg, MD, highlights recent study findings on the role for perioperative systemic therapy for renal cell carcinoma with a tumor thrombus. Recent findings from a retrospective study ...
Early treatment intensification with ADT and ARPIs is now standard for mCSPC, with patient-specific factors guiding therapy selection. Enzalutamide, apalutamide, abiraterone, and darolutamide are key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback